Martyn D. Greenacre - May 21, 2024 Form 4 Insider Report for CURIS INC (CRIS)

Role
Director
Signature
/s/ Diantha Duvall, Attorney-in-fact
Stock symbol
CRIS
Transactions as of
May 21, 2024
Transactions value $
$49,385
Form type
4
Date filed
5/23/2024, 04:07 PM
Previous filing
Jan 24, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRIS Non Qualified Stock Option Award $49.4K +4.25K $11.62 4.25K May 21, 2024 Common Stock 4.25K $11.62 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option grant, as disclosed in Curis Inc.'s 2024 proxy statement, was approved by the Board of Directors of Curis, Inc. on January 20, 2024, contingent upon shareholder approval of Curis's Fifth Amended and Restated 2010 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if the Fifth Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 21, 2024, at the 2024 annual meeting of shareholders, Curis's shareholders approved the Fifth Amended and Restated 2010 Plan.
F2 The option grant described in this Form 4 filing vests as to 100% of the underlying shares on January 20, 2025.